Evaluation of different artificial liver support therapy for acute-on-chronic liver failure: A prospective randomized control study.

Efficency and safety evaluation of different artificial liver support therapy for HBV related acute-on-chronic liver failure: A prospective randomized control study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036726

Enrollment

Unknown

Registered

2020-08-24

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver disease

Interventions

PE group:plasma exchange

PDF group:plasma dialysis filtration

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age range from 18 to 65 year; 2. History of chronic liver disease; 3. Total bilirubin >= 171µmol/L; 4. 1.5 < INR < 2.5 or 20% < PTA < 40%; 5. Participants signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactation period; 2. Hepatic encephalopathy grade III-IV; 3. Acute kidney Injury grand 2-3; 4. Active bleeding or disseminated intravascular coagulation; 5. Acute cardio-cerebral vascular accidents; 6. Uncontrolled diabetes or hypertension; 7. Malignancy(including HCC); 8. Organ transplant patients; 9. History of chronic kidney disease; 10. Histroy of decompensated liver cirrhosis.

Design outcomes

Primary

Measure	Time frame
total bilirubin;INR;	—

Secondary

Measure	Time frame
MELD score;inflammatory cytokines;Album;Globulin;Ammonia;creatine;	—

Countries

China

Contacts

Public ContactWei Yuan

Shanghai Public Health Clinical Center

yuanwei@shphc.org.cn+86 18121150010

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026